Overview

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin or carboplatin monotherapy) administered concurrent to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma) having platinum-sensitive relapse (platinum-free interval > 6 months).

Phase:

Phase 2

Details

Lead Sponsor:

North Eastern German Society of Gynaecological Oncology

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab